Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence.
about
Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patientsIncidence of adverse drug reactions in human immune deficiency virus-positive patients using highly active antiretroviral therapyEfavirenz and the CNS: what we already know and questions that need to be answeredSecondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.Baseline predictors of efavirenz-containing antiretroviral regimen adverse experiences.Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.Neurological and psychiatric adverse effects of antiretroviral drugs.Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz.Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers.Neuropsychiatric Effects of HIV Antiviral Medications.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 InfectionPharmacogenomics of antimicrobial agents.The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 InfectionPlasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial)Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.An update on the use of Atripla in the treatment of HIV in the United States.Long-term safety from the raltegravir clinical development program.Recognizing cognitive and psychiatric changes in the post-highly active antiretroviral therapy era.Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose.Neuropsychiatric side effects of efavirenz therapy.Efavirenz: a review.Psychiatric morbidity in HIV-infected children.Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW).Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration?Efavirenz: a decade of clinical experience in the treatment of HIV.Implications of efavirenz for neuropsychiatry: a review.Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010).A systematic review of the psychiatric side-effects of efavirenz.HIV and depression--a systematic review of interventions.Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.Switch strategies in antiretroviral therapy regimens.A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications.Markov model for characterizing neuropsychologic impairment and Monte Carlo simulation for optimizing efavirenz therapy.Impact of pharmacogenetics on CNS side effects related to efavirenz.Effect of Valerian in Preventing Neuropsychiatric Adverse Effects of Efavirenz in HIV-Positive Patients: A Pilot Randomized, Placebo-Controlled Clinical Trial.Depression and anxiety were low amongst virally suppressed, long-term treated HIV-infected individuals enrolled in a public sector antiretroviral program in Thailand.Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients.Quality of life and depression among HIV-infected patients receiving efavirenz- or protease inhibitor-based therapy in Senegal.
P2860
Q21245026-98C8C98C-63F1-484F-84EA-7DAE78BEC947Q24609339-96AA139E-4626-4878-BDE8-67201CF099D1Q28085028-FC059FF3-A8C1-4771-BA3F-B9CE08746177Q33909996-A810BFA9-29A1-492C-B4A3-32AF650C2766Q33910378-C5CC7E7E-1D48-4D52-8BD2-C74B21407715Q34035045-61D5CB57-F1B5-459C-8C58-00CBCE758297Q34039419-8F910EBF-994A-476E-BC9C-12FF91F2ACB9Q34310827-C20B75C6-EB76-404E-896E-887A120E4D85Q34464997-A8E4B523-9298-4492-975F-CBC96EFB45A3Q34531724-85795CF9-53B4-444C-94DF-B80EFC305C4BQ34537705-50DC9B49-3F47-43D5-984B-EF9E64FFFCCDQ34976284-F911FCD1-F32D-426F-BF3F-2C3B16F06F40Q34977413-5EA20621-BC95-4A55-B5F1-E73500B82F7BQ35111300-B1A108DB-0F6C-47A8-A436-2763538440EBQ35114865-FB9A3D93-BA23-416A-821E-0C1236FDB3BDQ35364120-0D031373-D52A-4A31-8910-B6F0B95736D3Q35547048-F986E1B5-6F51-4DF0-A8D7-5335CEEF71B4Q35557269-F918CD10-933F-4903-8FBE-40D177B8E05EQ35701258-D7EFB6B1-26D1-4820-BC47-3711418B427FQ36684274-1A004AB6-FE31-4112-9A0B-2DC3F6892109Q36729929-825E3F92-E732-4936-BB73-08C8A1BDF889Q36762436-C717BCDA-CCE3-49E3-B37A-671DCF39F559Q36787311-C851CDE0-C1FD-4C54-8F41-CD70E4A7B843Q36851079-340DC05F-3212-477F-AF5F-A7444278A3BDQ36994977-18BD5A9C-F2EF-4193-9BD7-FBE13504D09DQ37362071-9E33252B-6B27-42F6-8424-F81D0265954CQ37383949-B91958F4-F8A5-4A4A-9115-D41D2AB9A31BQ37801927-40BB9127-978D-4335-B5F8-414E1C0C5449Q37860335-0D656F25-F82D-4883-B253-6613B49BFE58Q37864141-686656BF-80EA-4171-A09B-1569856AFB13Q37910199-AE8DAD6A-BD87-40DA-9AA1-C0D5D68194DBQ38083294-256F75F8-6C94-494D-9FEA-15A25773C0A9Q38235295-363C4708-B63D-484F-8A46-004C66F99AE3Q38743628-A984FD6D-FD60-498D-A9BB-9D970D371E12Q38859179-E704E5CB-E4C9-47EC-9929-FA2B17E1E0B0Q39383647-2D73EE6C-9A32-4C1F-A062-1D499D6C02E9Q40223622-B0F07B58-9842-483C-9DAA-D496FE3BE262Q40523281-25F0800F-0F29-488B-861B-14B262658561Q40836288-C6CD00DA-A691-4C50-B462-E5229C4CF6F3Q42164244-2DA13C3C-C47A-4F60-A213-A66EF7B17EAD
P2860
Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Long-term neuropsychiatric dis ...... hologic issues, and adherence.
@en
Long-term neuropsychiatric dis ...... hologic issues, and adherence.
@nl
type
label
Long-term neuropsychiatric dis ...... hologic issues, and adherence.
@en
Long-term neuropsychiatric dis ...... hologic issues, and adherence.
@nl
prefLabel
Long-term neuropsychiatric dis ...... hologic issues, and adherence.
@en
Long-term neuropsychiatric dis ...... hologic issues, and adherence.
@nl
P2093
P50
P1476
Long-term neuropsychiatric dis ...... hologic issues, and adherence.
@en
P2093
Carmina R Fumaz
David Burger
Eugènia Negredo
Guillem Sirera
Maria José Ferrer
Núria Pérez-Alvarez
P304
P356
10.1097/01.QAI.0000147523.41993.47
P407
P50
P577
2005-04-01T00:00:00Z